• 6 min read
• Published on 25 July 2025
Listen to article
6:52Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
For what feels like an eternity, we British have treated mental health with the same stiff upper lip we reserve for bad weather and lukewarm tea. You just got on with it. But times, it seems, are changing. The conversation has finally opened up, and where conversation goes, capital is rarely far behind. I find myself looking at the burgeoning mental wellness sector not just as a social good, which it certainly is, but as a potentially fascinating, if complex, investment frontier. The question is, can you make a sensible return from the business of the mind?
Let’s be pragmatic. The sheer scale of the mental health crisis is, from a purely economic standpoint, an enormous market inefficiency. One in four of us, they say, will face a mental health issue each year. That’s a staggering number of people who might need help. For investors, this isn't about ambulance chasing. It's about recognising that a fundamental human need has been chronically underserved. The simple truth is that where there is a widespread problem, a market to solve it will eventually emerge. And the market for a sounder mind is, frankly, enormous. Companies are now tackling this from every conceivable angle, and it’s this diversity that I find particularly compelling.
Perhaps the most headline-grabbing part of this revolution is the so called psychedelic renaissance. Now, let's be clear, we are not talking about what your mate Dave brought back from a weekend in Amsterdam. This is the highly clinical, lab coat wearing, clipboard holding version of psychedelic medicine. Companies are conducting rigorous trials, using compounds like psilocybin to treat severe depression. The idea is not to manage symptoms with a daily pill, but to potentially rewire the brain’s pathways in a few supervised sessions. It’s a bold ambition, and the risks are plain to see. These treatments are years away from widespread use and depend entirely on navigating a minefield of clinical trials and regulatory approvals. Success is far from guaranteed, but the potential upside, should they succeed, is hard to ignore.
While psychedelics get the press, a quieter, perhaps more profound, revolution is happening on our phones and laptops. The idea of speaking to a therapist from the comfort of your own sofa, possibly while still in your pyjamas, would have seemed absurd a decade ago. Now, it’s a booming business. Telehealth platforms have torn down the old barriers of geography, cost, and stigma. This isn't just about convenience. It's a fundamental shift in the business model of healthcare. These digital platforms can scale at a speed traditional clinics can only dream of, and their potential to reach underserved communities is immense.
Before you get carried away on a wave of optimism, a dose of reality is in order. Investing here isn't a walk in the park. Many of these bright young companies are burning through cash, pinning their hopes on clinical trials that could, and sometimes do, fail spectacularly. The digital health space is becoming crowded, and competition could certainly squeeze profits. This is the sharp end of investing, where genuine innovation sits side by side with significant risk.
It’s a complex and fascinating field, one that requires a fair bit of homework. You have pioneers in psychedelics, digital platforms, and neuro-tech all vying for attention. For an investor, picking individual winners could be a tricky business. This is where a diversified approach might make sense, looking at a collection of companies in this space. A basket like The Mind & Spirit is designed to offer that broader exposure, bundling together the various players shaping this new frontier. It’s a way to invest in the theme itself, without betting the farm on a single, risky venture.
View the full Basket:Mind & Spirit
View the full Basket:Mind & Spirit
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article